The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1250 Weight Loss articles
Researchers analyzing over 30 million FDA safety reports found Wegovy associated with nearly five times higher odds of ischemic optic neuropathy (ION), or 'eye stroke,' compared to Ozempic. This sudden vision loss risk was strongest in men on Wegovy. While rare, these findings urge caution and further study for GLP-1 users.
Eli Lilly, the maker of blockbuster GLP-1 drug Mounjaro, has signed a landmark $2.7 billion deal with AI drug discovery firm Insilico Medicine. This agreement builds on their 2023 software licensing pact and harnesses Insilico's AI engine to fast-track novel therapeutics across multiple areas. Patients and investors are watching closely for impacts on metabolic health innovations.
Robert F. Kennedy Jr., US health secretary nominee, wants to open sales of restricted injectable peptides, fitting his Make America Healthy Again agenda. While some peptides show promise, the FDA halted 17 in 2023 due to safety risks—without trials, anecdote isn't evidence. This editorial warns against sidelining regulation for wellness hucksters.
The surge in GLP-1 medications is revolutionizing not just health but fashion retail, with 23% of U.S. households now using drugs like Ozempic and Wegovy. This rapid weight loss is shrinking demand for plus-size clothing, pressuring retailers like Torrid and DXL. Yet, opportunities emerge in transitional wardrobes and long-term inclusivity.
More Americans are turning to GLP-1 drugs like Wegovy for weight loss, but experts warn of a critical error. The biggest mistake, says obesity specialist Dr. Katherine Saunders, is treating the prescription as the full treatment. Pairing meds with healthy habits amplifies benefits and sustains results.
The VanEck Pharmaceutical ETF (PPH) offers broad pharma exposure but faces headwinds from U.S. drug pricing reforms and heavy Eli Lilly weighting. Down 8% in the past month despite 15% one-year gains, PPH's diversification is tested. Key risks include MFN pricing deals and GLP-1 competition.
Reports claim jockeys are turning to Ozempic for rapid weight loss, sparking debate on whether semaglutide should join WADA's Prohibited List. With WADA's 2024 Monitoring Program underway and research into performance effects, the drug's potential benefits and risks in sports like cycling and horse racing are under the microscope. Could this GLP-1 agonist redefine fair play in weight-class sports?
India's metabolic therapy market is shifting dramatically after semaglutide's patent expiry, slashing prices by 85-90% and unlocking demand for 75-80 million obese individuals. Ajanta Pharma gears up for generic semaglutide launch, while Sun Pharma leverages innovations for sustained growth. Analysts forecast the GLP-1 segment scaling to INR34-67 billion in 3-5 years amid rising specialist adoption.
In a Phase 2 clinical trial in China, Novo Nordisk's experimental drug UBT251 surpassed Ozempic, achieving greater reductions in blood sugar (up to 2.16% HbA1c drop) and body weight (up to 9.8% loss). This marks a potential advancement for type 2 diabetes management. Patients on semaglutide saw 1.77% HbA1c and 4.8% weight reductions, while placebo groups lagged behind.
